RxDoctor Payments Data

Amanda Coniglio, MD

Cardiovascular Disease · Rochester, NYNPI 1518344159

Payments from drug & device makers

$60,060in general payments, 2019–2025

Across 180 payments — averaging $333.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alnylam Pharmaceuticals Inc.$36K
  • Pfizer$12K
  • Bridgebio Pharma, Inc.$8K
  • Medtronic$932
  • Abbott$569
  • Actelion Pharmaceuticals US, Inc.$435
  • plus $2K from 21 others

What the payments were for

  • Consulting fees$17,82330%
  • Speaking & faculty fees$31,97353%
  • Travel & lodging$5,3039%
  • Food & beverage$4,7528%
  • Education$2110%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$60,060 in reported general payments places this provider in the 90th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$43,437
Medicare patients
141
Services billed
420

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan87$125,281
JardianceEmpagliflozin80$104,214
FarxigaDapagliflozin Propanediol46$51,424
EliquisApixaban14$22,221
OzempicSemaglutide15$16,936
Torsemide60$2,504
Midodrine Hcl14$1,950
Metoprolol Succinate109$1,785
Spironolactone112$868
Eplerenone11$853
Rosuvastatin Calcium33$768
Atorvastatin Calcium44$568
Carvedilol34$308
Amiodarone Hcl15$265
Furosemide40$255

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$135$125,28187 claims
Boehringer IngelheimJardiance$63$104,21480 claims
AstraZenecaFarxiga$336$51,42446 claims
PfizerEliquis$11,977$22,22114 claims
Novo NordiskOzempic$78$16,93615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Rochester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →